Skip to main content

01.12.2012 | Review | Ausgabe 1/2012 Open Access

Cancer Cell International 1/2012

New insights into antigen specific immunotherapy for chronic myeloid leukemia

Cancer Cell International > Ausgabe 1/2012
Yangqiu Li, Chen Lin, Christian A Schmidt
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contribution

The concept of this paper was devised by YQL. YQL, CL and CAS contributed to the intellectual input of the paper. All authors read and approved the final manuscript.


Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as an oncoprotein and a molecular and immunogenic target. Despite the success of targeted therapy using tyrosine kinase inhibitors (TKIs), CML remains largely incurable, most likely due to the treatment resistance of leukemic stem cells. Several immunotherapies have been developed for CML in different stages and relapse after allogeneic stem cell transplantation. In the this review, several specific immunotherapeutic approaches for CML, including vaccination and adoptive cellular immunotherapy, are discussed along with results from clinical trials, and the value of such immunotherapies in the era of imatinib and leukemia-associated antigens (LAAs), which are capable of inducing specific T cell responses and are appropriate target structures for the immunological targeting of CML cells, are also summarized.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Cancer Cell International 1/2012 Zur Ausgabe